Study of Cardiometabolic Markers Along with Lipid Indices in Psoriasis

Abstract

Background: Psoriasis is one of the most common chronic inflammatory skin diseases which affects 2-4% of the general population. The results of epidemiological studies have demonstrated that the risk to develop cardiovascular disease (CVD) is higher in patients with severe psoriasis. The pathogenesis of atherosclerosis followed by CVD is inflammation dependent in psoriasis.
Material and Methods: It is a cross sectional observation study conducted in a tertiary care hospital from January 2019 to January 2021. 110 patients with psoriasis were included in cases and 110 controls. Anthropometric markers viz. blood pressure (BP), abdominal circumference and cardiometabolic markers lipid profile, hs-CRP, uric acid, Lp(a) were estimated in both groups. The data obtained was subjected to appropriate statistical analysis.
Results: Anthropometric markers BP (136.1 ± 14.0/ 81.4 ± 8.3; 125.0 ± 8.9/ 76.2 ± 5.5) and abdominal circumference (85.4 ± 15.3; 44.7 ± 11.9), BMI (40.9 ± 8.3; 22.3 ± 3.2) were statistically high in cases than controls. The cardiometabolic markers as Triglycerides (TG) ( 212.3 ± 39.5; 122.9 ± 43.2), Total cholesterol (241.0 ± 60.4; 155.0 ± 43.2), High Density Lipoprotein-Cholesterol (HDL-C) ( 34.9 ± 6.8; 43.5 ± 9.8), Low Density Lipoprotein-Cholesterol (LDL-C) (196.8 ± 43.1; 132.0 ± 10.0), uric acid (17.1 ± 7.2; 4.5 ± 1.0), hs-CRP ( 16.2 ± 7.7; 2.8 ± 1.3), Lipoprotein (a) [Lp(a)] ( 41.3 ± 8.7; 25.1 ± 7.9) and lipid indices AIP (0.79 ± 0.12, 0.46 ± 0.11), CI-I (7.20 ± 2.43; 3.70 ± 1.13), CI-II (5.85 ± 1.70; 3.21 ± 0.83), AC (239.97 ± 60.44; 152.25 ± 35.05), LTI (6654.34 ± 39207.47; 92.29 ± 38.92) were significantly high in cases compared to controls.
Conclusion: The present study found significant increase in cardiometabolic markers in psoriasis patients compared to controls. So, this study emphasizes the importance of screening of cardiometabolic markers and other metabolic comorbidities in psoriasis patients to help in early detection and treatment in order to reduce cardiovascular events.